Daniel Santa Mina1,2,3, Darren Au1,2, Leslie E Auger4, Shabbir M H Alibhai3,5, Andrew G Matthew2,3,6, Catherine M Sabiston1, Paul Oh3,7, Paul G Ritvo8, Eugene B Chang2,3, Jennifer M Jones2,3. 1. Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, Ontario, Canada. 2. Department of Supportive Care, Princess Margaret Cancer Centre, Toronto, Ontario, Canada. 3. Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. 4. Kinesiology Program, University of Guelph-Humber, Toronto, Ontario, Canada. 5. Toronto General Research Institute, Toronto General Hospital, Toronto, Ontario, Canada. 6. Department of Surgery, Princess Margaret Cancer Centre, Toronto, Ontario, Canada. 7. Cardiovascular Prevention and Rehabilitation Program, Toronto Rehabilitation Institute, Toronto, Ontario, Canada. 8. School of Kinesiology and Health Sciences, York University, Toronto, Ontario, Canada.
Abstract
BACKGROUND: National and international bodies acknowledge the benefit of exercise for people with cancer, yet limited accessibility to related programing remains. Given their involvement in managing the disease, cancer centers can play a central role in delivering exercise-oncology services. The authors developed and implemented a clinically integrated exercise-oncology program at a major cancer center and evaluated its effectiveness and participant experience. METHODS: A hospital-based program with prescribed at-home exercise was developed and accepted referrals over a 42-month period (3.5 years). Implementation was conducted in 2 phases: a pilot phase for women with breast cancer and men with genitourinary cancer and a roll-out phase for all patients with cancer. Enrolled patients were assessed and received an exercise prescription as well as a program manual, resistance bands, and a stability ball from a kinesiologist. Program participation and effectiveness were evaluated up to 48 weeks after the baseline assessment using intention-to-treat analyses. Participants in the roll-out phase were asked to complete a program experience questionnaire at the completion of the 48-week follow-up. RESULTS: In total, 112 participants enrolled in the pilot, and 150 enrolled in the roll-out phase. Program attrition to 48 weeks was 48% and 65% in the pilot and roll-out phases, respectively. In participants who consented to research evaluation of their performance, objective and patient-reported measures of functional capacity improved significantly from baseline in both phases. Participants were highly satisfied with the program. CONCLUSIONS: Despite significant drop-out to program endpoints, our cancer-exercise program demonstrated clinically relevant improvement in functional outcomes and was highly appreciated by participants.
BACKGROUND: National and international bodies acknowledge the benefit of exercise for people with cancer, yet limited accessibility to related programing remains. Given their involvement in managing the disease, cancer centers can play a central role in delivering exercise-oncology services. The authors developed and implemented a clinically integrated exercise-oncology program at a major cancer center and evaluated its effectiveness and participant experience. METHODS: A hospital-based program with prescribed at-home exercise was developed and accepted referrals over a 42-month period (3.5 years). Implementation was conducted in 2 phases: a pilot phase for women with breast cancer and men with genitourinary cancer and a roll-out phase for all patients with cancer. Enrolled patients were assessed and received an exercise prescription as well as a program manual, resistance bands, and a stability ball from a kinesiologist. Program participation and effectiveness were evaluated up to 48 weeks after the baseline assessment using intention-to-treat analyses. Participants in the roll-out phase were asked to complete a program experience questionnaire at the completion of the 48-week follow-up. RESULTS: In total, 112 participants enrolled in the pilot, and 150 enrolled in the roll-out phase. Program attrition to 48 weeks was 48% and 65% in the pilot and roll-out phases, respectively. In participants who consented to research evaluation of their performance, objective and patient-reported measures of functional capacity improved significantly from baseline in both phases. Participants were highly satisfied with the program. CONCLUSIONS: Despite significant drop-out to program endpoints, our cancer-exercise program demonstrated clinically relevant improvement in functional outcomes and was highly appreciated by participants.
Authors: Maria Queralt Salas; Eshetu G Atenafu; Ora Bascom; Leeann Wilson; Wilson Lam; Arjun Datt Law; Ivan Pasic; Dennis Dong Hwan Kim; Fotios V Michelis; Zeyad Al-Shaibani; Armin Gerbitz; Auro Viswabandya; Jeffrey Howard Lipton; Jonas Mattsson; Shabbir M H Alibhai; Rajat Kumar Journal: Bone Marrow Transplant Date: 2020-06-30 Impact factor: 5.483
Authors: Kelley R Covington; Timothy Marshall; Grace Campbell; Grant R Williams; Jack B Fu; Tiffany D Kendig; Nancy Howe; Catherine M Alfano; Mackenzi Pergolotti Journal: Support Care Cancer Date: 2021-04-26 Impact factor: 3.603
Authors: Amy M Dennett; Bernadette Zappa; Rachel Wong; Stephen B Ting; Kimberley Williams; Casey L Peiris Journal: Support Care Cancer Date: 2021-05-08 Impact factor: 3.603
Authors: Margaret L McNeely; Christopher Sellar; Tanya Williamson; Melissa Shea-Budgell; Anil Abraham Joy; Harold Y Lau; Jacob C Easaw; Albert D Murtha; Jeffrey Vallance; Kerry Courneya; John R Mackey; Matthew Parliament; Nicole Culos-Reed Journal: BMJ Open Date: 2019-09-13 Impact factor: 2.692
Authors: Adriana M Coletta; Nathan B Rose; Austin F Johnson; D Scott Moxon; Stephen K Trapp; Darren Walker; Shelley White; Cornelia M Ulrich; Neeraj Agarwal; Sonal Oza; Rebecca W Zingg; Pamela A Hansen Journal: Support Care Cancer Date: 2021-01-27 Impact factor: 3.603
Authors: Louise Czosnek; Justin Richards; Eva Zopf; Prue Cormie; Simon Rosenbaum; Nicole M Rankin Journal: BMC Cancer Date: 2021-05-30 Impact factor: 4.430
Authors: Scott C Adams; Anika Petrella; Catherine M Sabiston; Madison F Vani; Abha Gupta; Linda Trinh; Andrew G Matthew; Robert J Hamilton; Daniel Santa Mina Journal: Support Care Cancer Date: 2021-01-06 Impact factor: 3.359
Authors: Scott C Adams; Jenna Smith-Turchyn; Daniel Santa Mina; Sarah Neil-Sztramko; Prue Cormie; S Nicole Culos-Reed; Kristin L Campbell; Gemma Pugh; David Langelier; Kathryn H Schmitz; David J Phipps; Michelle Nadler; Catherine M Sabiston Journal: Front Oncol Date: 2021-07-19 Impact factor: 6.244